NCT07561190 Multidimensional Omics Analysis in Malignant Pleural Mesothelioma
| NCT ID | NCT07561190 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda USL Reggio Emilia - IRCCS |
| Condition | Malignant Pleural Mesothelioma (MPM) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-08-30 |
| Primary Completion | 2024-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-08-30 with a primary completion date of 2024-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited. The lack of prognostic biomarkers further complicates the decision-making. Recently, the introduction of immune checkpoint inhibitors (ICIs) has marked a shift but has failed to produce significant benefits for a large proportion of patients. Maximizing the efficiency of ICIs and developing new protocols to improve drug efficacy is the best possible strategy for improving the life expectancy and quality of life of patients with MPM. This study aims to characterize the organization of the immune system infiltrating mesothelioma and the dynamics of its interaction with the tumor. The rationale is that deciphering this complexity will help improve our understanding of the mechanisms underlying this disease and provide a new tool to optimize the use of ICIs in these patients.
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Aged \> 18 years * Patients with histologically confirmed diagnosis of MPM * Availability of biological material * Clinical indicatio of eligibility for HITOCH protocol (only for C3 cohort) Exclusion Criteria: * Active current infection * Autoimmune disease * Women in childbearing age not able to exclude pregnancy
Contact & Investigator
Alessia Ciarrocchi
PRINCIPAL INVESTIGATOR
Azienda USL - IRCCS di Reggio Emilia
Frequently Asked Questions
Who can join the NCT07561190 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Pleural Mesothelioma (MPM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07561190 currently recruiting?
Yes, NCT07561190 is actively recruiting participants. Contact the research team at alessia.ciarrocchi@ausl.re.it for enrollment information.
Where is the NCT07561190 trial being conducted?
This trial is being conducted at Catania, Italy, Naples, Italy, Reggio Emilia, Italy, Roma, Italy.
Who is sponsoring the NCT07561190 clinical trial?
NCT07561190 is sponsored by Azienda USL Reggio Emilia - IRCCS. The principal investigator is Alessia Ciarrocchi at Azienda USL - IRCCS di Reggio Emilia. The trial plans to enroll 300 participants.